The Phase 3 PAPILLON study demonstrated that RYBREVANT with carboplatin and pemetrexed significantly enhances progression-free survival in NSCLC patients with EGFR exon 20 insertion mutations.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing